Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials.
Cancer Med
; 12(8): 9392-9400, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36880426
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias del Recto
/
Neoplasias Colorrectales
/
Neoplasias del Colon
/
ADN Tumoral Circulante
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Cancer Med
Año:
2023
Tipo del documento:
Article